May 8, 2009
Results From Phase 3 EQUATE Trial Of VIVUS' Qnexa Highlighted At European Congress On Obesity
VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that data from the previously reported 28-week phase 3 EQUATE trial of Qnexa(TM) in obese patients are being presented at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands. The results, titled "Weight Loss at 6 Months with VI-0521 Treatment," will be presented at the Hot Topic poster session by Donna H. Ryan, M.D. SHARETHIS.addEntry({ title: "", url: "" });
Spread the word
Leave a Comment